Trial Profile
A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Abicipar pegol (Primary) ; Ranibizumab
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors Allergan
- 27 Oct 2016 Data from this trial were presented at the 2016 American Academy of Ophthalmology Annual Meeting, according to an Allergan media release.
- 10 Oct 2016 According to Allergan media release, new data will be presented at the 2016 American Academy of Ophthalmology Annual Meeting in Chicago.
- 13 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.